News

a.z
(2022). . , 77(6), 2415-2421. doi: 10.22092/ari.2022.358363.2208
. "". , 77, 6, 2022, 2415-2421. doi: 10.22092/ari.2022.358363.2208
(2022). '', , 77(6), pp. 2415-2421. doi: 10.22092/ari.2022.358363.2208
. , 2022; 77(6): 2415-2421. doi: 10.22092/ari.2022.358363.2208

Archives of Razi Institute
Article 49, Volume 77, Issue 6, January and February 0, Pages 2415-2421    PDF (606.47 K)
Document Type: مقالات پژوهشی
DOI: 10.22092/ari.2022.358363.2208
Supplementary Files
References
  1. Gao Z, Xu Y, Sun C, Wang X, Guo Y, Qiu S, et al. A systematic review of asymptomatic infections with COVID-19. J Microbiol Immunol Infect. 2021;54(1):12-6.
  2. Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020;50(4):332-4.
  3. Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924.
  4. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846-8.
  5. Lin C, Ding Y, Xie B, Sun Z, Li X, Chen Z, et al. Asymptomatic novel coronavirus pneumonia patient outside Wuhan: the value of CT images in the course of the disease. Clin Imaging. 2020;63:7-9.
  6. Warusevitane A, Karunatilake D, Sim J, Smith C, Roffe C. Early diagnosis of pneumonia in severe stroke: clinical features and the diagnostic role of C-reactive protein. PloS one. 2016;11(3):e0150269.
  7. Velavan TP, Meyer CG. The COVID‐19 epidemic. Tropical medicine & international health. 2020;25(3):278.
  8. Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127:104370.
  9. Soni M. Evaluation of eosinopenia as a diagnostic and prognostic indicator in COVID‐19 infection. Int J Lab Hematol. 2021;43:137-41.
  10. Mousavi SA, Rad S, Rostami T, Rostami M, Mousavi SA, Mirhoseini SA, et al. Hematologic predictors of mortality in hospitalized patients with COVID-19: a comparative study. Hematology. 2020;25(1):383-8.
  11. Sanchez‐Pina JM, Rodríguez Rodriguez M, Castro Quismondo N, Gil Manso R, Colmenares R, Gil Alos D, et al. Clinical course and risk factors for mortality from COVID‐19 in patients with haematological malignancies. Eur J Haematol. 2020;105(5):597-607.
  12. Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HH, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020;81(1):e6-e12.
  13. Querol-Ribelles JM, Tenias JM, Grau E, Querol-Borras JM, Climent JL, Gomez E, et al. Plasma d-dimer levels correlate with outcomes in patients with community-acquired pneumonia. Chest. 2004;126(4):1087-92.
  14. Commission NH. Translation: Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7). Infect Microbes Dis. 2020;2(2):48-54.
  15. Usul E, Şan İ, Bekgöz B, Şahin A. Role of hematological parameters in COVID-19 patients in the emergency room. Biomark Med. 2020;14(13):1207-15.
  16. Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun. 2020;11(1):1-10.
  17. Klein SL, Morgan R. The impact of sex and gender on immunotherapy outcomes. Biol Sex Differ. 2020;11(1):1-10.
  18. Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis. 2020.
  19. Organization WH. Coronavirus disease 2019 (COVID-19): situation report, 73. 2020.
  20. Di Gennaro F, Pizzol D, Marotta C, Antunes M, Racalbuto V, Veronese N, et al. Coronavirus diseases (COVID-19) current status and future perspectives: a narrative review. Int J Environ Res Public Health. 2020;17(8):2690.
  21. Zahorec R, Hulin I, Zahorec P. Rationale Use of Neutrophil-to-lymphocyte ratio for early diagnosis and stratification of COVID-19.  Bratisl Lek Listy. 2020;121(7):466-70.
  22. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-2.
  23. Bajgain KT, Badal S, Bajgain BB, Santana MJ. Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature. Am J Infect Control. 2021;49(2):238-46.
  24. Wang W, Wang Y, Qu C, Wang S, Zhou J, Cao W, et al. The RNA genome of hepatitis E virus robustly triggers an antiviral interferon response. Hepatology. 2018;67(6):2096-112.
  25. Kwon JH, Jang JW, Kim YW, Lee SW, Nam SW, Jaegal D, et al. The usefulness of C-reactive protein and neutrophil-to-lymphocyte ratio for predicting the outcome in hospitalized patients with liver cirrhosis. BMC Gastroenterol. 2015;15(1):1-7.
  26. Al-Khafaji NS, Abdulla AA, Kunwar PS, Mohammed SS, Mohammed RK, Al-Marzoki AH, et al. Coronaviruses seven outbreaks associated with OC43, 229E, severe acute respiratory syndrome-CoV1, NL63, HKU1, Middle East respiratory syndrome coronavirus, and severe acute respiratory syndrome-CoV2. Drug Invent Today. 2020;13(6).
  1. Wool GD, Miller JL. The impact of COVID-19 disease on platelets and coagulation. Pathobiology. 2021;88(1):15-27.
  2. Cekerevac I, Turnic TN, Draginic N, Andjic M, Zivkovic V, Simovic S, et al. Predicting severity and intrahospital mortality in COVID-19: the place and role of oxidative stress. Oxid Med Cell Longev. 2021;2021.
  3. Pimentel MA, Redfern OC, Hatch R, Young JD, Tarassenko L, Watkinson PJ. Trajectories of vital signs in patients with COVID-19. Resuscitation. 2020;156:99-106.
  4. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473-4.
  5. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020;53:25-32.
  6. Fox SE, Akmatbekov A, Harbert JL, Li G, Brown JQ, Vander Heide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med. 2020;8(7):681-6.
  7. Gong J, Dong H, Xia Q, Huang Z, Wang D, Zhao Y, et al. Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19 pneumonia. MedRxiv. 2020.
  8. Honore PM, Hoste E, Molnár Z, Jacobs R, Joannes-Boyau O, Malbrain ML, et al. Cytokine removal in human septic shock: where are we and where are we going? Ann Intensive Care. 2019;9(1):1-13.
  9. Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell‐induced severe or life‐threatening cytokine release syndrome. Oncologist. 2018;23(8):943-7.
  10. Chan AS, Rout A. Use of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in COVID-19. J Clin Med Res. 2020;12(7):448.
  11. Lagunas‐Rangel FA. Neutrophil‐to‐lymphocyte ratio and lymphocyte‐to‐C‐reactive protein ratio in patients with severe coronavirus disease 2019 (COVID‐19): a meta‐analysis. J Med Virol. 2020.
Statistics
Article View: 15,351
PDF Download: 67,290


counter
Journal management system. designed by sinaweb